{"id":{"repo_id":"sdstate","oai_identifier":"oai:openprairie.sdstate.edu:etd2-2893"},"canonical_url":"https://search.ndltd.org/etd/sdstate/oai:openprairie.sdstate.edu:etd2-2893","repository":{"repo_id":"sdstate","name":"South Dakota State University","base_url":"https://openprairie.sdstate.edu/do/oai/"},"display":{"title":"Formulation and Immunogenicity of L1 ORF1 MRNA Vaccine in Mice","abstract":"This dissertation presents the design, formulation, and immunogenicity evaluation of a novel mRNA vaccine targeting the L1 ORF1p protein, a tumor-associated antigen. The vaccine was synthesized using in vitro transcription and encapsulated in lipid nanoparticles (LNPs), with both unmodified uridine and N1-methylpseudouridine variants tested. Physicochemical characterization confirmed optimal particle size (160–220 nm), acceptable zeta potential, and encapsulation efficiency ranging from 74% to 92%, with preserved RNA integrity post-formulation. These results validate the robustness of the formulation workflow and its suitability for antigen delivery. Immunogenicity studies in C57BL/6 mice revealed modest but promising immune responses. While early activation markers (CD69) and memory T cell populations (CD44⁺CD62L⁺) showed upward trends, they did not reach statistical significance likely due to timing of sample collection and limited cohort size. Notably, the low-dose uridine-formulated group demonstrated significant increases in IFN-γ and TNF-α production in both CD4⁺ and CD8⁺ T cells upon stimulation, indicating functional T cell activation. ELISpot assays supported these findings, though elevated background responses in controls suggest non-specific activation. Despite some inconclusive data, this study establishes a strong foundation for future research. It highlights the importance of dose optimization, timing of analysis, and assay refinement. The results support the potential of L1 ORF1p as a viable target for cancer immunotherapy and provide a reproducible framework for mRNA-LNP vaccine development.","abstract_html":"This dissertation presents the design, formulation, and immunogenicity evaluation of a novel mRNA vaccine targeting the L1 ORF1p protein, a tumor-associated antigen. The vaccine was synthesized using in vitro transcription and encapsulated in lipid nanoparticles (LNPs), with both unmodified uridine and N1-methylpseudouridine variants tested. Physicochemical characterization confirmed optimal particle size (160–220 nm), acceptable zeta potential, and encapsulation efficiency ranging from 74% to 92%, with preserved RNA integrity post-formulation. These results validate the robustness of the formulation workflow and its suitability for antigen delivery. Immunogenicity studies in C57BL/6 mice revealed modest but promising immune responses. While early activation markers (CD69) and memory T cell populations (CD44⁺CD62L⁺) showed upward trends, they did not reach statistical significance likely due to timing of sample collection and limited cohort size. Notably, the low-dose uridine-formulated group demonstrated significant increases in IFN-γ and TNF-α production in both CD4⁺ and CD8⁺ T cells upon stimulation, indicating functional T cell activation. ELISpot assays supported these findings, though elevated background responses in controls suggest non-specific activation. Despite some inconclusive data, this study establishes a strong foundation for future research. It highlights the importance of dose optimization, timing of analysis, and assay refinement. The results support the potential of L1 ORF1p as a viable target for cancer immunotherapy and provide a reproducible framework for mRNA-LNP vaccine development.","abstract_has_math":false,"creators":["Nandani, Raj"],"institution":null,"degree_name":"Doctor of Philosophy (PhD)","degree_level":"Dissertation - Open Access","degree_discipline":"Pharmaceutical Sciences","degree_department":null,"school":null,"contributors":["Wenfeng An"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T09:05:56Z","subjects":["Pharmacy and Pharmaceutical Sciences"],"languages":[],"rights":[],"rights_urls":["http://rightsstatements.org/vocab/InC/1.0/"],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://openprairie.sdstate.edu/etd2/1889","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://openprairie.sdstate.edu/etd2/1889","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://openprairie.sdstate.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Aopenprairie.sdstate.edu%3Aetd2-2893","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Wenfeng An"]},{"key":"dc:creator","label":"Author","values":["Nandani, Raj"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2026-01-29T08:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2025-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmaceutical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation - Open Access"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (PhD)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Pharmacy and Pharmaceutical Sciences"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:rights","label":"Dc Rights","values":["http://rightsstatements.org/vocab/InC/1.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://openprairie.sdstate.edu/etd2/1889"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["This dissertation presents the design, formulation, and immunogenicity evaluation of a novel mRNA vaccine targeting the L1 ORF1p protein, a tumor-associated antigen. The vaccine was synthesized using in vitro transcription and encapsulated in lipid nanoparticles (LNPs), with both unmodified uridine and N1-methylpseudouridine variants tested. Physicochemical characterization confirmed optimal particle size (160–220 nm), acceptable zeta potential, and encapsulation efficiency ranging from 74% to 92%, with preserved RNA integrity post-formulation. These results validate the robustness of the formulation workflow and its suitability for antigen delivery. Immunogenicity studies in C57BL/6 mice revealed modest but promising immune responses. While early activation markers (CD69) and memory T cell populations (CD44⁺CD62L⁺) showed upward trends, they did not reach statistical significance likely due to timing of sample collection and limited cohort size. Notably, the low-dose uridine-formulated group demonstrated significant increases in IFN-γ and TNF-α production in both CD4⁺ and CD8⁺ T cells upon stimulation, indicating functional T cell activation. ELISpot assays supported these findings, though elevated background responses in controls suggest non-specific activation. Despite some inconclusive data, this study establishes a strong foundation for future research. It highlights the importance of dose optimization, timing of analysis, and assay refinement. The results support the potential of L1 ORF1p as a viable target for cancer immunotherapy and provide a reproducible framework for mRNA-LNP vaccine development."]},{"key":"dc:title","label":"Title","values":["Formulation and Immunogenicity of L1 ORF1 MRNA Vaccine in Mice"]}]}],"canonical_facts":{"dc:contributor":["Wenfeng An"],"dc:creator":["Nandani, Raj"],"dc:date.available":["2026-01-29T08:00:00Z"],"dc:date.created":["2025-01-01T08:00:00Z"],"dc:description.abstract":["This dissertation presents the design, formulation, and immunogenicity evaluation of a novel mRNA vaccine targeting the L1 ORF1p protein, a tumor-associated antigen. The vaccine was synthesized using in vitro transcription and encapsulated in lipid nanoparticles (LNPs), with both unmodified uridine and N1-methylpseudouridine variants tested. Physicochemical characterization confirmed optimal particle size (160–220 nm), acceptable zeta potential, and encapsulation efficiency ranging from 74% to 92%, with preserved RNA integrity post-formulation. These results validate the robustness of the formulation workflow and its suitability for antigen delivery. Immunogenicity studies in C57BL/6 mice revealed modest but promising immune responses. While early activation markers (CD69) and memory T cell populations (CD44⁺CD62L⁺) showed upward trends, they did not reach statistical significance likely due to timing of sample collection and limited cohort size. Notably, the low-dose uridine-formulated group demonstrated significant increases in IFN-γ and TNF-α production in both CD4⁺ and CD8⁺ T cells upon stimulation, indicating functional T cell activation. ELISpot assays supported these findings, though elevated background responses in controls suggest non-specific activation. Despite some inconclusive data, this study establishes a strong foundation for future research. It highlights the importance of dose optimization, timing of analysis, and assay refinement. The results support the potential of L1 ORF1p as a viable target for cancer immunotherapy and provide a reproducible framework for mRNA-LNP vaccine development."],"dc:identifier":["https://openprairie.sdstate.edu/etd2/1889"],"dc:rights":["http://rightsstatements.org/vocab/InC/1.0/"],"dc:subject":["Pharmacy and Pharmaceutical Sciences"],"dc:title":["Formulation and Immunogenicity of L1 ORF1 MRNA Vaccine in Mice"],"thesis:degree_discipline":["Pharmaceutical Sciences"],"thesis:degree_level":["Dissertation - Open Access"],"thesis:degree_name":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-11-19T09:05:56Z"}